Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms

INTRODUCTION: Myopia is a major cause of degenerative eye disease and increases the risk of secondary visual impairment. Mitigating its progression therefore has great potential of clinically relevant benefit as shown by using highly diluted atropine eye drops in children of Asian origin. However, l...

Descripción completa

Detalles Bibliográficos
Autores principales: Farassat, Navid, Böhringer, Daniel, Küchlin, Sebastian, Molnár, Fanni E, Schwietering, Anne, Seger, Dorina, Hug, Martin J, Knöbel, Anja-Birte, Schneider-Fuchs, Sabine, Ihorst, Gabriele, Wabbels, Bettina, Beisse, Christina, Ziemssen, Focke, Schuettauf, Frank, Hedergott, Andrea, Ring-Mangold, Theresia, Schuart, Claudia, Wolf, Armin, Schmickler, Stefanie, Biermann, Julia, Eberwein, Philipp, Hufendiek, Karsten, Eckstein, Anja, Gusek-Schneider, Gabriele, Schittkowski, Michael, Lischka, Thomas, Lagrèze, Wolf A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124292/
https://www.ncbi.nlm.nih.gov/pubmed/37080623
http://dx.doi.org/10.1136/bmjopen-2022-068822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124292/
https://www.ncbi.nlm.nih.gov/pubmed/37080623
http://dx.doi.org/10.1136/bmjopen-2022-068822

Ejemplares similares